Abstract
Objectives To quantify the morbidity (years lived with disability; YLDs) of long COVID in Australia during the 2021-2022 Omicron BA.1/BA.2 wave.
To compare long COVID YLDs with: acute SARS-CoV-2 infection YLDs; years of life lost (YLLs) from SARS-CoV-2; and health loss from other diseases.
Design Burden of disease study using inputs from previously published case-control, cross-sectional, or cohort studies.
Setting Australia
Participants People with symptomatic SARS-CoV-2 infection from 10/12/21 to 09/04/22.
Main outcomes measured YLDs from long COVID per SARS-CoV-2 infection were estimated as the product of the prevalence, duration, and severity of each long COVID symptom.
YLDs from acute-SARS-CoV-2 infection and YLLs from deaths were also estimated.
The sum of the above three components was total COVID-19 disability-adjusted life years (DALYs).
Results 5,200 (95% uncertainty interval [UI] 2,100-8,300) YLDs were attributable to long COVID, 1,800 (95% UI 1,100-2,600) to acute-SARS-CoV-2 infection, meaning long COVID caused 74% of the overall YLDs from SARS-CoV-2 infections in the BA.1/BA.2 wave.
Total DALYs attributable to SARS-CoV-2 were 50,900 (95% UI 21,000-80,800), 2.4% of expected DALYs for all diseases in the same period.
Conclusion Improved data on long COVID will improve the accuracy of morbidity estimates. In parallel, as data accumulates on SARS-CoV-2 infection sequelae (e.g., increased cardiovascular disease rates), total health loss is likely to be higher than estimated in this study.
Nevertheless, this study demonstrates that long COVID requires consideration in pandemic policy planning given it is responsible for the majority of direct SARS-CoV-2 morbidity, including during an Omicron wave in a highly vaccinated population.
Introduction
A post-acute phase of SARS-CoV-2 infection, commonly termed long COVID, occurs among some individuals following acute infection. Long COVID describes the persistence and/or emergence of a heterogeneous group of symptoms at least 12 weeks after acute infection.1 There is no current consensus on the symptom profile that specifically characterises long COVID, with a wide range of symptoms being reported (Table 1).2 While some studies report symptom clustering within individuals, the frequency and significance of this remains unclear and individuals most commonly report experiencing one or two symptoms.3,4 The aetiology of long COVID is proposed to be related to continued immune activation and persistence of the virus in the various organ systems infected during the acute period.5 Numerous risk factors have been identified, including a propensity towards an autoimmune response, female sex, co-morbidities such as Type 2 Diabetes Mellitus, and a more severe acute infection.4,6 Importantly, COVID-19 vaccination has been found to reduce the risk of long COVID.7,8
Given ongoing high rates of SARS-CoV-2 transmission globally, it is important to quantify the full health impact of SARS-CoV-2 infection, including its longer-term consequences. Recent burden of disease studies have quantified long COVID by treating it as a single outcome, utilising the Global Burden of Disease (GBD) study health state of ‘post-acute consequences’ from other respiratory illnesses, or chronic fatigue syndrome, to approximate long COVID severity.9-11 While these health states have some overlap with documented long COVID symptoms, they do not acknowledge the full breadth of symptoms linked to long COVID, or the heterogeneity of symptoms reported between individuals.2,9
A lack of high-quality evidence regarding the prevalence and duration of symptoms hampers quantification of the long COVID burden. Many studies of long COVID lack an appropriate control group or are subject to other methodological issues. Of particular concern is selection bias from self-selection into studies by those experiencing ongoing symptoms and loss-to-follow up by those no longer symptomatic. These biases likely inflate estimates of long COVID occurrence.
Conversely, studies with insufficient follow-up time may not capture the full burden of long COVID symptoms, which are often relapsing and remitting in nature.2 In addition to these design issues, the majority of published long COVID research has been conducted in cohorts of unvaccinated, pre-Omicron variant infected cases. To accurately quantify the impact of long COVID in highly vaccinated populations during Omicron waves, differences in the risk of long COVID by vaccination and variant need incorporating.
This paper addressed the following research questions: firstly, what is the extent of the morbidity attributable to long COVID resulting from Omicron variant SARS-CoV-2 infections, quantified ‘bottom-up’ from occurrence rates of each symptom and its severity and duration? Secondly, what proportion of total Disability-Adjusted Life Years (DALYs) accumulated during the 2021-2022 Omicron wave in Australia were due to long COVID, and how does this health loss compare to other major causes of health loss in Australia?
Methods
Morbidity calculations
Long COVID morbidity was calculated as that expected per symptomatic SARS-CoV-2 infected person:
where i and j indexes each possible symptom, and Prevalencei only is the prevalence of symptom i minus the sum of the joint occurrence of symptom i with each other symptom (assuming symptom occurrence is independent). The prevalence of each symptom was calculated as a risk difference in symptom frequency between SARS-CoV-2 survivors and SARS-CoV-2-negative controls, extracted from previous research (Appendix 1).3,12-4 The severity of each symptom was quantified as a disability weight (DW) taken from the GBD study 15 for the matching health state, and best matches otherwise (e.g. DWs of other sensory conditions have been used as proxies for dysosmia and dysgeusia). Severityi and j was calculated as 16:
It was assumed that only initially symptomatic patients are at risk of long COVID 17, and that calculations including all three-way (or higher) combinations of symptoms would make negligible difference.
The above ‘base case’ prevalence calculations were for unvaccinated individuals infected with a pre-Omicron variant of SARS-CoV-2, and were split into three sub-groups: adult community cases, adult hospitalised cases, and children (any acute disease severity).3,12-4 Long COVID symptom prevalence among previously hospitalised adults is approximately twice that among community cases.12 Symptom prevalence is also lower among children (0-17 years) compared to adults.14 Duration of each symptom (from 1-week post-infection for mild/moderate cases, and 4-weeks post-infection for those hospitalised) was applied based on recent findings by Wulf Hansen et al., who reported a median duration of symptoms for community infections of 4 months, and 8.9 months for previously hospitalised cases.18 Exceptions to this have been applied to psychological symptoms, for which a shorter duration was used, and similarly for children (see Table 2).13,19
These base-case prevalence’s were then multiplied by an odds ratio (OR) of 0.55 to approximate symptom prevalence among vaccinated cases based on findings from two recent studies that found reduced odds of symptoms following the acute infection by 49% and 41%, for those who had at least two COVID-19 vaccines compared to one/no vaccines.7,8 (Vaccination post-infection has been found to have a limited effect on long COVID occurrence – therefore, only vaccination prior to infection was considered.20,21) Next, prevalence estimates were further multiplied by an OR of 0.25 based on an estimate of the reduction in prevalence of any symptoms at least 4-weeks post-infection for Omicron variant compared to Delta variant infections in a vaccinated cohort in the United Kingdom.22 It was assumed that this association remains beyond 12 weeks post-infection. The exception to the latter multiplier was adults hospitalised with an Omicron infection; we assumed that once a case is severe enough to be hospitalised, there is no difference in resulting long COVID compared to pre-Omicron variants.
Uncertainty in base case (i.e. unvaccinated and pre-Omicron infected) long COVID estimates was modelled in a bottom-up manner (i.e. using the uncertainty about all inputs; detailed in Appendix 2), and equated to a standard deviation of +/- 20% of the expected value. For morbidity calculations for vaccinated and Omicron-infected populations, we used a standard deviation of +/- 30% of the expected value to reflect the additional uncertainty.
Application to the Omicron wave and health burden comparison
Long COVID years lived with disability (YLDs) were calculated as the expected long COVID morbidity per symptomatic case multiplied by the total number of symptomatic infections (treated as equivalent to notified cases) during the four months of the Omicron BA.1/BA.2 wave in Australia, defined here as December 10th 2021 to April 9th 2022.
The YLDs from acute SARS-CoV-2 infection were estimated as detailed in Appendix 3.
Years of life lost (YLLs) due to SARS-CoV-2 deaths were estimated using standard burden of disease methods 23, multiplying deaths due to COVID-19 with the average remaining life expectancy of those who died (with reference life expectancy by sex and age obtained from the 2019 GBD, retrieved from the Institute for Health Metrics and Evaluation [IHME] results tool).24
YLL and YLD calculations were by strata of age, hospitalisation status and vaccination. The total DALYs from SARS-CoV-2 infection in these four months was just the sum of the above three components. Note that for the purposes of this paper, we ‘repatriated’ the long COVID YLDs to the SARS-CoV-2 infections occurring in the four month window.
For comparison, we took the YLDs and DALYs in Australia for other diseases from GBD 2019 24, dividing by three to make them equivalent to the four-month duration of the BA.1/BA.2 wave.
Results
Morbidity estimates
Long COVID morbidity prevalence and decay over time for each symptom for unvaccinated pre-Omicron infection, are presented in Appendix 4. Table 2 shows the DW used for each symptom, and the estimated prevalence and average duration of that symptom among Omicron infected, unvaccinated cases; the prevalence among vaccinated cases is that shown multiplied by 0.55.
The total long COVID morbidity estimates for each sub-group are shown in Table 3.
Application to the Omicron wave
Some 4.87 million COVID-19 cases were notified in Australia during the first four months of the Omicron wave, with approximately 35,500 hospitalisations and 3,463 deaths (Appendix 5). An estimated 61% of notified cases were vaccinated at the time of infection (Appendix 5).
The overall morbidity (i.e. YLDs) resulting from infections in this period, including acute and long COVID is shown in Figure 1. Long COVID accounts for approximately 74% of the overall non-fatal COVID-19 health loss among notified cases during the first 4 months of the Australian Omicron wave, at 5,200 YLDs (95% uncertainty interval [UI] 2,100-8,300)
95% uncertainty intervals are shown for long COVID YLD estimates, measured with +/- 30% standard deviation. Total morbidity (rightmost bar) is estimated at 7,000 YLDs. YLDs= Years Lived with Disability
The overall DALYs resulting from COVID-19 infections in the four-month period was estimated at 50,900 (95% UI 21,000-80,800), of which long COVID contributed 10.2% (compared to the acute COVID-19 morbidity contribution of 3.6%).
The leading 25 causes of morbidity in Australia ranked by YLDs are presented in Figure 2 along with the estimated YLDs resulting from COVID-19 cases during the first four months of the Omicron wave. Total COVID-19 morbidity is ranked 24th, comparable to the non-fatal health loss resulting from chronic kidney disease.
COVID-19 YLDs, separated as long COVID (blue) and acute COVID-19 (red) includes the future morbidity resulting from long COVID for these cases (long COVID also presented separately). 95% uncertainty intervals are shown for total COVID-19 and long COVID YLD estimates, measured using +/- 30% standard deviation. YLDs for other outcomes are estimated from the 2019 GBD study, and have been divided by 3 to estimate health loss over a 4-month period.20
COPD= Chronic Obstructive Pulmonary Disease; CKD= Chronic Kidney Disease; T2DM= Type 2 Diabetes Mellitus; YLD= Years Lived with Disability.
The leading 25 causes of health loss in Australia ranked by DALYs, are presented in Figure 3 along with the estimated DALYs resulting from the first four months of the COVID-19 Omicron wave. The DALYs resulting from COVID-19 cases are estimated to be 2.4% of all expected DALY loss in the four months, and rank 10th among conditions (between Alzheimer’s and other dementias, and drug use disorders). The 95% uncertainty interval indicates that the rank could in fact be as high as 3rd (between low back pain and falls) or as low as 24th (below alcohol use disorders).
COVID-19 DALYs, separated as YLD (purple) and YLL (red), include the future morbidity resulting from long COVID for these cases (long COVID also presented separately). 95% uncertainty intervals are shown for total COVID-19 and long COVID DALYs, measured using +/- 30% standard deviation. DALYs for other outcomes are estimated from the 2019 GBD study, and have been divided by 3 to estimate health loss over a 4-month period.20
COPD= Chronic Obstructive Pulmonary Disease; CKD= Chronic Kidney Disease; DALY= Disability-Adjusted Life Years; T2DM= Type 2 Diabetes Mellitus.
Discussion
This is the first publication to quantify the overall health burden of COVID-19 throughout the Omicron wave in Australia. We found that long COVID contributed to approximately 74% of the non-fatal health loss resulting from COVID-19 infections in the first four months of this wave, with the total YLDs comparable to that caused by chronic kidney disease and ischaemic heart disease (Figure 2). Also significant is the overall COVID-19 disease burden calculated in this study, amounting to 50,900 DALYs over the initial four months of the Omicron wave, or the 10th highest cause of DALYs in a 4-month period in Australia (Figure 3).
The strengths of this study lie in the comprehensive approach applied to quantify long COVID morbidity across multiple patient sub-groups, and consideration of the impact of vaccination and the Omicron variant on long COVID incidence. This has not been undertaken in other studies to our knowledge. Our approach also allows for a more complete profile of symptoms, rather than treating long COVID as a single outcome. The health state ‘post-acute consequences’, applied by two recent Australian publications to estimate the long COVID health burden in Australia, encompasses fatigue, depression and body pain.10,11,15 By treating long COVID as a single entity, these studies assume that the average long COVID sufferer has all the symptoms included within this applied health state. A recent study by the Institute of Health Metrics quantified long COVID parameters across three separate symptom groups (cognitive difficulty, fatigue, and shortness of breath). 18 In a supplementary analysis (Appendix 6), we calculated long COVID morbidity with the IHME’s estimates, and found comparable results, indicating our method and the IHME method are consistent.
This study has limitations. Long COVID is an area of rapidly emerging and evolving research, currently characterised by limited high-quality literature. As such, there is a high level of uncertainty in our findings (e.g., our ‘cross-walk’ of pre-Omicron unvaccinated data to Omicron (largely) vaccinated cases). The studies utilised for our prevalence estimates were included based on an assessment of bias and methodological quality; however, prevalence may still be overestimated, due to the likely direction of bias to over-estimation in long COVID studies.
One-way sensitivity analyses conducted to determine the contribution of each morbidity parameter to overall uncertainty in long COVID morbidity, found the greatest contribution came from severity estimates (Appendix 7). This is of concern, given that the majority of DWs applied were made by estimation from other health states 15, and points to the merit of research to better quantify severity of each long COVID symptom. Additionally, cognitive and psychological symptoms both contributed to a high level of uncertainty in overall estimates, despite only being a small proportion of the overall symptoms included in this analysis, also indicating a need for further research on the prevalence and severity of these symptoms (Appendix 7).
It is important to note that many people dying of COVID-19 have co-morbidities, so their true YLLs will be less than that measured using standard DALY methods, which assumes those dying of COVID-19 have the mortality rate specified in the reference life table.
Our findings highlight the need to factor in long COVID-related health loss when making policy decisions, in the context of the continuing Omicron wave. Whilst the prevalence of long COVID symptoms is less now among highly vaccinated populations with Omicron than it was for pre-Omicron variants among unvaccinated populations, long COVID still contributes substantial health loss when summed over all infections. The knowledge from this paper may therefore provide an imperative for policymakers to better address the healthcare needs of long COVID sufferers – few evidence-based management options currently exist.25,26 Specific areas of need may require prioritisation, for example psychological support for those previously hospitalised with COVID-19, for whom such symptoms are relatively common.13
Our analysis focused on long COVID symptoms occurring in the months following infection. However, SARS-CoV-2 infection has also been associated with persistent organ damage, and an increased risk of chronic conditions including Type 2 Diabetes Mellitus and cardiovascular disease, particularly among those who had a severe acute infection.27,31 Longer-term research will be required in the future to determine the extent that SARS-CoV-2 infection causes these sequelae, which will lead to the total burden of SARS-CoV-2 being greater (perhaps considerably greater) than that quantified in this study.
Data Availability
All data/sources used for quantitative analysis can be made available by authors on reasonable request.
Footnotes
Funding: no funding
Sponsors: no sponsors
Ethical approval: This study did not require ethical approval.
Patient and public involvement: This study included no patient/public involvement.
Trial registration: N/A
joshua.szanyi{at}unimelb.edu.au
antony.blakely{at}unimelb.edu.au
Main text updated; Table 2 updated; Appendix updated.
References
